Nishi Masaaki, Shimada Mistuo, Yoshikawa Kozo, Higashijima Jun, Tokunaga Takuya, Kashihara Hideya, Takasu Chie, Ishikawa Daichi, Wada Yuma, Eto Shohei
Department of Surgery, Tokushima University.
J Med Invest. 2018;65(1.2):27-31. doi: 10.2152/jmi.65.27.
Surgical indication for hepatic resection is controversial in gastric cancer liver metastasis (GLM). The aim of this study is to clarify the effect of hepatic resection for GLM.
Ten patients who underwent hepatic resection for GLM between 2001 and 2013 were enrolled in this study. Six patients underwent synchronous hepatic resection and gastrectomy, and the remaining four patients underwent metachronous hepatic resection. Six patients had solitary liver metastasis, and 4 patients had multiple liver metastasis. The median follow-up period was 12.4 months (the range being 0.5 months to 50 months).
The actual 1- year and 3-year overall survival rates for the patients who underwent hepatic resection are 88.9% and 17.8%, respectively. The median survival time was 21.5 months. And the 1-year recurrence free survival time was 20.0%. The median recurrence free survival rate was 4.7 months. Regarding post-operative recurrence, synchronous hepatic resection tended to be a recurrence factor (p=0.08).
Hepatic resection for GLM has an acceptable outcome. Metachronous hepatic resection tends to have a better outcome than synchronous hepatic resection for the treatment of GLM. J. Med. Invest. 65:27-31, February, 2018.
胃癌肝转移(GLM)患者肝切除的手术指征存在争议。本研究旨在阐明肝切除治疗GLM的效果。
本研究纳入了2001年至2013年间接受肝切除治疗GLM的10例患者。6例患者接受了同期肝切除和胃切除术,其余4例患者接受了异时性肝切除。6例患者为孤立性肝转移,4例患者为多发性肝转移。中位随访期为12.4个月(范围为0.5个月至50个月)。
接受肝切除患者的实际1年和3年总生存率分别为88.9%和17.8%。中位生存时间为21.5个月。1年无复发生存时间为20.0%。中位无复发生存率为4.7个月。关于术后复发,同期肝切除倾向于成为复发因素(p = 0.08)。
肝切除治疗GLM有可接受的结果。对于GLM的治疗,异时性肝切除的效果往往优于同期肝切除。《医学调查杂志》65:27 - 31,2018年2月。